Alwyn Mwinga
Director/Board Member at Drugs for Neglected Diseases initiative
Profile
Alwyn Mwinga is currently the Director at Drugs for Neglected Diseases initiative.
She has a graduate degree from the University of London and a graduate degree from the University of Zambia.
Alwyn Mwinga active positions
Companies | Position | Start |
---|---|---|
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Director/Board Member | - |
Training of Alwyn Mwinga
University of London | Graduate Degree |
University of Zambia | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Alwyn Mwinga